Loading...
XNASELDN
Market cap240mUSD
Jan 16, Last price  
4.03USD
1D
-0.49%
1Q
35.69%
Jan 2017
-54.21%
IPO
-79.62%
Name

Eledon Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ELDN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
117.98%
Rev. gr., 5y
%
Revenues
0k
00000000120,000000
Net income
-40m
L-53.92%
-9,649,000-15,725,000-23,296,000-45,087,000-37,959,000-13,116,000-14,065,000-17,878,000-22,811,000-34,506,000-87,504,000-40,326,000
CFO
-40m
L+39.06%
-9,333,000-15,476,000-21,121,000-41,236,000-36,520,000-14,941,000-11,893,000-13,857,000-15,212,000-28,913,000-28,424,000-39,527,000
Earnings
Mar 26, 2025

Profile

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
URL
https://eledon.com/
IPO date
Sep 17, 2014
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
43,374
40,153
Unusual Expense (Income)
NOPBT
(43,374)
(40,153)
NOPBT Margin
Operating Taxes
(462)
Tax Rate
NOPAT
(43,374)
(39,691)
Net income
(40,326)
-53.92%
(87,504)
153.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
33,017
BB yield
-74.51%
Debt
Debt current
766
363
Long-term debt
383
1,129
Deferred revenue
(2)
Other long-term liabilities
76,211
2
Net debt
(49,953)
(54,917)
Cash flow
Cash from operating activities
(39,527)
(28,424)
CAPEX
Cash from investing activities
(45,287)
Cash from financing activities
33,017
FCF
(44,898)
(39,662)
Balance
Cash
51,102
56,409
Long term investments
Excess cash
51,102
56,409
Stockholders' equity
(319,378)
(202,851)
Invested Capital
403,563
287,780
ROIC
ROCE
EV
Common stock shares outstanding
24,619
14,285
Price
1.80
-21.05%
2.28
-48.30%
Market cap
44,315
36.06%
32,570
-50.16%
EV
(5,638)
(22,347)
EBITDA
(43,000)
(39,780)
EV/EBITDA
0.13
0.56
Interest
462
Interest/NOPBT